& Biotechnology News, shows that Humira occupied the position for 2015 () and 2016 () 2017: AbbVie reports that Humira achieved of sales in 2017. 2021 March: Nature reports that HUMIRA had the largest worldwide drugs sale across 2019 and 2020 of US$19.7bn and US$20.4bn respectively. Society and culture Economics The UK NHS in 2019 listed Humira, Amgevita, Hulio, Hyrimoz, Idacio, and Imraldi as biosimilars available on (almost free) prescription, to be updated in February 2022. The annual cost of adalimumab, the costliest NHS drug, was expected to drop from £400m to £100m by 2021, the biggest saving in NHS history from a single drug negotiation. Biosimilars From 2012, until the US patent expired in 2016, Humira led the list of top-selling pharmaceutical products, and in 2016, it had of global sales. From 2014, biosimilars were manufactured by several companies and sold at a lower price than before patent expiry. In 2014, Indian drugmaker Cadila Healthcare declared the launch of the first adalimumab biosimilar at a fifth of its US price. The generic was launched under the brand name Exemptia. In 2016, Indian drugmaker Torrent Pharmaceuticals launched its biosimilar for adalimumab, called Adfrar. It was the second generic biosimilar of adalimumab. In September 2016, the FDA approved Amgen's biosimilar adalimumab-atto, sold under the brand name Amjevita. Amjevita will not be available in the US until at least February 2023. In August 2017, the FDA approved German pharmaceutical company Boehringer Ingelheim's biosimilar, Cyltezo. In 2017, the biosimilars Amgevita, Solymbic, Imraldi, and Cyltezo were approved for use in the European Union. In 2018, the biosimilars Halimatoz, Hefiya, Hyrimoz, and Hulio were approved for use in the European Union. Adalimumab biosimilars became available in the European Union in 2018, allowing the National Health Service to make record-breaking cost-savings, as this is the single most expensive drug used in NHS hospitals, costing more than £400million a year for about 46,000 patients. In October 2018, adalimumab-adaz (Hyrimoz) was approved for use in the United States. In April 2019, Idacio and Kromeya were approved for use in the European Union. In July 2019, adalimumab-bwwd (Hadlima), produced by Samsung Bioepsis, was approved for use in the US. However, it will not be available until at least June 2023, after the availability of Amgen's offering as a result of a negotiated intellectual property settlement with AbbVie. In November 2019, adalimumab-afzb (Abrilada) was approved for use in the United